Molecular mechanisms of dilated cardiomyopathy

描述（由申请人提供）：心血管疾病仍然是世界范围内死亡和残疾的主要原因。肥厚型心肌病（HCM）、扩张型心肌病（DCM）通常进展为收缩性心力衰竭（HF），这是美国死亡的主要原因。然而，这些心血管疾病的分子机制尚未完全了解。我们确定CIP作为一种新的心脏特异性核蛋白，并证明CIP调节心肌细胞肥大和扩张型心肌病。本研究的总体目标是揭示CIP在心脏和心脏疾病中的生理和病理功能。具体目标是：具体目标#1。确定CIP在心脏中的体内功能。具体目标#2。检验CIP预防HCM进展为DCM和心力衰竭的假设。具体目标#3明确CIP调控HCM和DCM的分子机制。这项研究将为我们理解心脏功能和心肌病的分子事件提供重要的见解，并且是开发纠正或规避心血管疾病的治疗策略的重要先决条件。

DESCRIPTION (provided by applicant): Cardiovascular diseases continue to be a leading cause of death and disability world- wide. Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) often progress to systolic heart failure (HF), the leading cause of death in the U.S. However, the molecular mechanisms underlying these cardiovascular disorders are not fully understood. We identified CIP as a novel cardiac-specific nuclear protein and demonstrated that CIP modulates cardiomyocyte hypertrophy and dilated cardiomyopathy. The overall goal of our study is to uncover the physiological and pathological functions of CIP in the heart and heart diseases. The specific aims are: Specific Aim #1. To determine the in vivo function of CIP in the heart. Specific Aim #2. To test the hypothesis that CIP prevents the progression of HCM to DCM and heart failure. Specific Aim #3. To define the molecular mechanism by which CIP regulates HCM and DCM. This study will provide important insights into our understanding the molecular events underlying cardiac function and cardiomyopathy and are an important prerequisite to developing therapeutic strategies that correct or circumvent cardiovascular diseases.